Day 1: ESMO Sarcoma & GIST Faculty closed meeting

Transcription

1 Day 1: ESMO Sarcoma & GIST Faculty closed meeting Sunday, 4 February :30 14:00 Lunch 14:00-16:00 Discussion: Should we routinely use NGS? 120 Panel discussion 16:00 16:30 Coffee Break 16:30-18:00 Discussion: Will we use immune therapy also in STS & GIST? 60 Panel discussion

2 Day 2a: Soft tissue sarcoma (STS) & Gastrointestinal stromal tumours (GIST): Preceptorship Educational sessions for Junior audience Monday, 5 February :30-11:00 Session 1 The diseases 25 The natural history of STS & GIST P.G. Casali, IT 25 The pathology of STS & GIST A.P. Dei Tos, IT 25 The clinical genetics of GIST M. Pantaleo, IT 15 Discussion 11:00-11:30 Coffee Break 11:30-13:00 Session 2 Principles of local treatment 30 Surgical margins in STS & GIST P. Hohenberger, DE 30 Principles of radiation therapy in STS R.L. Haas, NL 30 Retroperitoneal sarcomas S. Bonvalot, FR 13:00-14:00 Lunch 14:00-15:00 60 Session 3 Multidisciplinary treatment in the localised-disease setting 30 Adjuvant chemotherapy of STS J.-Y. Blay, FR 30 Adjuvant therapy of GIST H. Joensuu, FI 15:00-15:30 Coffee Break 15:30-18: Session 4 The medical approach in the advanced-disease setting 30 Principles of systemic therapy of STS B. Kasper, DE 30 Histology- and molecularly-driven medical therapy of STS R. Jones, UK 30 Targeted therapy of metastatic GIST P. Reichardt, DE 30 Practical management of TKI treatment in GIST A. LeCesne, FR 30 Immune therapy of STS & GIST J.-Y. Blay, FR GOAL To provide an audience of clinicians (namely, young oncologists) who are not expert in the disease with the basic principles of treatment of STS and GIST

3 Day 2b - Soft tissue sarcoma (STS) & Gastrointestinal stromal tumours (GIST): Advanced for expert audience Monday, 5 February :30-11:00 Session 1 Localised GIST: Case discussions Panelists: TBD 11:00-11:30 Coffee Break 11:30-13:00 Session 2 Metastatic GIST: Case discussions Panelists : TBD 13:00-14:00 Lunch 14:00-15:30 Session 3 Localised STS: Case discussions Panelists: TBD 15:30-16:00 Coffee Break 16:00-17:30 Session 4 Metastatic STS: Case discussions Panelists: TBD GOAL To highlight problematic and controversial clinical issues in current treatment of STS & GIST, by exposing an audience of clinicians treating STS and GIST to a variety of challenging clinical cases, discussed by panels made up of both European and American experts

4 Day 3 & 4: 7TH ESMO SYMPOSIUM ON SARCOMA & GIST Tuesday, 6 February : Opening & Welcome 10 Welcome by ESMO P.G. Casali, IT 10 Welcome by INT - Milan G. Apolone, IT 10 Welcome by SPAEN M. Wartenberg, DE 08:30-09:50 80 Session 1 State of the art 20 Pathology and genetics of STS C. Fletcher, US 20 The medical treatment of STS S. Patel, US 20 The GIST genotypes relevant to therapy S. Bauer, DE 20 The medical treatment of GIST H. Joensuu, FI 09:50-10:20 Coffee Break 10:20-12: Session 2 - Surgery 20 Why is the sarcoma surgical margin different from the C. Raut, US epithelial? 20 Should we stratify the surgical margin across STS A. Gronchi, IT histologies? 20 How the surgical margin has changed in retroperitoneal C.J. Swallow, US sarcomas? 20 When surgery should be done in desmoids? S. Bonvalot, FR 20 Has surgery of lung metastases in sarcomas evolved from P. Hohenberger, DE the XIX century on? 20 Is the GIST surgical margin different? P. Rutkowski, PL 12:30-13:30 Lunch 13:30-14:30 Industry Satellite Symposium 1 14:40-16:10 Session 3 Radiation therapy 20 Does radiation therapy improve survival in STS? R. Haas, NL 20 Is preoperative radiation therapy better? C. Catton, CA 20 Is there a rationale for radiation therapy in retroperitoneal E.H. Baldini, US sarcomas? 20 Should we use proton or carbon ion radiation therapy in T.F. DeLaney, US any STS today? 16:10-16:40 Coffee Break

5 Tuesday, 6 February 2018, cont. 16:40-19: Session 4 - Chemotherapy 20 Can we reach a consensus on the value of neoadjuvant & R.S. Benjamin, US adjuvant chemotherapy in STS? 20 Can the pathologist say if a patient has responded to A.P. Dei Tos, IT preoperative chemotherapy? 20 Can we get to an evidence-based histology-driven P.G. Casali, IT chemotherapy in advanced STS? 20 Are we prolonging survival with chemotherapy in A. LeCesne, FR metastatic STS? 20 The case of uterine sarcomas S. George, US 20 The case of histiocytic/dendritic cell neoplasms A.M. Frezza, IT 20 Discussion 19:10-20:10 Industry Satellite Symposium 2 Wednesday, 7 February :00-10: Session 5 Targeted therapy of GIST & STS Chairs TBC 20 The clinical usefulness of profiling wild-type GIST J. Trent, US 20 The clinical management of TKIs in GIST P. Reichardt, DE 20 Current and future molecular biology of secondary J. Fletcher, US resistance in GIST 20 Current and future approach to secondary resistance in G. Demetri, US GIST 20 Actually actionable targets in STS P. Schoffski, BE 20 Histology-agnostic NGS for therapy in STS? A. Wagner, US 20 Can we get to an evidence-based targeted therapy of S. Stacchiotti, IT rare STS histologies? 20 Epigenetics and new avenues in STS M. Gounder, US 10:50-11:20 Coffee break 11: Session 7 Immune therapy Chairs TBC 20 Will we get to an evidence-based immune therapy in R. Maki, US STS? 20 Mutational load and immune microenvironment in STS J.-Y. Blay, FR and in the STS patient 20 Is there a rationale for immune therapy in GIST? R. DeMatteo, US 20 Should we combine immune therapy agents with what? S. D Angelo, US 20 Next-generation immune therapy in STS W. Tap, US 20 Will adoptive immune therapy be the way forward in cold L. Helman, US STS? 13:30-14:20 Lunch 14:20-15:20 Industry Satellite Symposium 3

6 Wednesday, 7 February 2018, cont. 15:30-17: Session 8 Round table with SPAEN Chairs TBC 15 Does evidence-based medicine discriminate the sarcoma P. Bruzzi, IT patient? 15 A patient perspective Speaker TBC 15 Can we improve the pathologic diagnosis in STS? A.P. Dei Tos 15 A patient perspective Speaker TBC 15 Will ERN improve quality of care of STS & GIST in the P.G. Casali EU? 15 A patient perspective Speaker TBC 25 Discussion 17:25-17:30 5 Conclusions 5 Take-home message: The value of multidisciplinarity in STS & GIST P.G. Casali